20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects.... View More